Heidelberg Pharma Reveals Promising Data on HDP-101 at ASH 2024

Heidelberg Pharma AG announced that new clinical data on their leading antibody-drug conjugate (ADC), HDP-101, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) in December 2024. The presentation, led by Dr. Robert Z. Orlowski from MD Anderson Cancer Center, will cover findings from the ongoing Phase I/IIa study targeting relapsed or refractory multiple myeloma.

Advancing to its sixth cohort, the study has shown promising results, including complete remission in a patient from the fifth cohort. Furthermore, several patients have displayed significant biological activity and improvements, indicating HDP-101's potential as a viable treatment for multiple myeloma.

This presentation underscores the innovative application of Amanitin-based ADC technology by Heidelberg Pharma. The ADC HDP-101 itself is a BCMA-targeting therapy offering new hope for patients unresponsive to other treatments, reinforcing its role in the evolving landscape of cancer therapy.